A phase II trial of interleukin-2 and interferon Alfa-2a in patients with advanced renal cell carcinoma Journal Article
| Authors: | Ilson, D. H.; Motzer, R. J.; Kradin, R. L.; Vogelzang, N. J.; Bajorin, D. F.; Scher, H. I.; Nanus, D.; O'Moore, P.; Marathias, K.; Bosl, G. J. |
| Article Title: | A phase II trial of interleukin-2 and interferon Alfa-2a in patients with advanced renal cell carcinoma |
| Abstract: | Purpose: A phase II trial that used a regimen of interieukin-2 (IL-2) and Interferon alfa-2a (IFN-α) was undertaken to evaluate the efficacy of this combination in the treatment of metastatic renal cell carcinoma. Patients and Methods: Thirty-four assessable patients were treated with one to two induction cycles of IL-2 administered by continuous intravenous (IV) infusion at a dose of 3 × 106 μ/m2/d for 4 days per week plus IFN-α administered by subcutaneous injection at a dose of 5 × 106 μ/m2d for 4 days per week for 3 consecutive weeks. A maintenance regimen of IL-2 2×106 μ/m2/d given by continuous IV infusion for 5 days per week plus IFN-α subcutaneously at a dose of 6 × 106 μ/m2/d that was given 3 days per week for 3 weeks was administered for one to five cycles. Twenty-eight patients (82%) completed one to two induction cycles, and 14 patients (41%) received maintenance doses. Results: Major responses were achieved in four patients (12%), which included one complete response (CR) in a bone metastasis. Responses were observed in patients both with and without prior nephrectomy as well as in a primary tumor. Toxicity was moderately severe and included two treatment-related deaths. Conclusions: In view of the minimal antitumor activity and associated toxicity, the combination of IL-2 and IFN-α in this trial cannot be recommended. The investigation of new cytokines and the identification of biologic prognostic factors for a response to immunologic therapy are essential. © 1992 by American Society of Clinical Oncology. |
| Keywords: | adult; cancer survival; clinical article; human tissue; treatment outcome; aged; survival analysis; human cell; bone metastasis; interleukin 2; cancer immunotherapy; lung toxicity; nephrotoxicity; phase 2 clinical trial; blood toxicity; antineoplastic combined chemotherapy protocols; drug administration schedule; kidney carcinoma; kidney neoplasms; drug fatality; gastrointestinal toxicity; hypotension; pethidine; carcinoma, renal cell; paracetamol; indometacin; ambulatory care; remission induction; alpha2a interferon; drug therapy; prochlorperazine; intravenous drug administration; interleukin-2; diphenhydramine; intramuscular drug administration; middle age; drug evaluation; interferon alfa-2a; subcutaneous drug administration; human; male; female; priority journal; article; support, non-u.s. gov't; support, u.s. gov't, p.h.s. |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 10 |
| Issue: | 7 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 1992-01-01 |
| Start Page: | 1124 |
| End Page: | 1130 |
| Language: | English |
| DOI: | 10.1200/jco.1992.10.7.1124 |
| PUBMED: | 1607918 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 30 July 2019 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work